Viewing Study NCT04934618


Ignite Creation Date: 2025-12-25 @ 5:03 AM
Ignite Modification Date: 2025-12-26 @ 4:05 AM
Study NCT ID: NCT04934618
Status: UNKNOWN
Last Update Posted: 2021-06-22
First Post: 2021-06-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Sponsor: Nanfang Hospital, Southern Medical University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module